Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan in Children With Short Stature (REAL 9)
NCT05723835Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of somapacitan in Small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome, Idiopathic Short Stature (ISS), sponsored by Novo Nordisk. Started Feb 2023; status: active, not recruiting.
02
Drugs
somapacitan
03
Conditions
Small for gestational age (SGA)Turner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NCT05723835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723835.